Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease

Toxics

Liliana Łykowska-Szuber¹  Michał Walczak²  Joanna Żuraszek²  Oliwia Zakerska-Banaszak²  Marzena Skrzypczak-Zielińska²  Aleksandra Zielińska² 

[1] Department of Gastroenterology, Dietetics and Internal Diseases, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355 Poznan, Poland;Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland;

关键词: thiopurines;    azathioprine;    mercaptopurine;    thioguanine;    cytotoxicity;    inflammatory bowel disease;   

DOI  :  10.3390/toxics10040151

来源: DOAJ

【 摘 要 】

The effectiveness of thiopurine drugs in inflammatory bowel disease (IBD) was confirmed more than a half-century ago. It was proven that these can be essential immunomodulatory medications. Since then, they have been used routinely to maintain remission of Crohn’s disease (CD) and ulcerative colitis (UC). The cytotoxic properties of thiopurines and the numerous adverse effects of the treatment are controversial. However, the research subject of their pharmacology, therapy monitoring, and the search for predictive markers are still very relevant. In this article, we provide an overview of the current knowledge and findings in the field of thiopurines in IBD, focusing on the aspect of their cytotoxicity. Due to thiopurines’ benefits in IBD therapy, it is expected that they will still constitute an essential part of the CD and UC treatment algorithm. More studies are still required on the modulation of the action of thiopurines in combination therapy and their interaction with the gut microbiota.

【 授权许可】

Unknown